Sugi Predict

Sugi Predict / Compounds / SCHEMBL1597577

SCHEMBL1597577

SCHEMBL1597577

Clc1cnc2cccnc2n1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 3/20 0.46
▸ ACHE P22303 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.41
▸ NR4A2 P43354 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPK14 Q16539 1/20 0.37
▸ RPS6KA5 O75582 1/20 0.37
▸ RPS6KA4 O75676 1/20 0.37
▸ GRM5 P41594 2/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CASP6 P55212 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11604764 0.98 BCHE (0.45) BCHEACHEALDH1A1NR4A2TDP1
SCHEMBL1597974 0.83 ALDH1A1 (0.41) BCHEACHEALDH1A1NR4A2TDP1
SCHEMBL9978592 0.76 ALDH1A1 (0.43) ALDH1A1KDM4ERPS6KA5RPS6KA4NPC1
SCHEMBL2928822 0.75 BCHE (0.46) BCHEACHEALDH1A1KDM4EMAPK14
SCHEMBL22479749 0.75 BCHE (0.46) BCHEACHEALDH1A1TDP1KDM4E
SCHEMBL1104821 0.75 BCHE (0.54) BCHEACHEALDH1A1KDM4EMAPK14
SCHEMBL6930663 0.75 BCHE (0.43) BCHEACHEALDH1A1NR4A2KDM4E
SCHEMBL362277 0.74 TDP1 (0.54) BCHEACHEALDH1A1NR4A2TDP1
Hydrochloric Acid SCHEMBL11604964 0.73 BCHE (0.45) BCHEACHEALDH1A1KDM4EMAPK14
SCHEMBL30731286 0.73 SMN1; SMN2 (0.53) BCHEALDH1A1TDP1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4590396-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2025-07-30 — — EP disclosed
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-04 — — US disclosed
WO-2024062089-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-03-28 — — WO disclosed
US-20230102554-A1 HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF GB002, INC. 2023-03-30 — — US disclosed
EP-3990443-A1 HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF GB002, Inc. (US) 2022-05-04 — — EP disclosed
WO-2021058592-A1 HERBICIDAL COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2021-04-01 — — WO disclosed
WO-2020264420-A1 HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF GB002, INC. (US) 2020-12-30 — — WO disclosed
WO-2020264420-A1 HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF GB002, INC. (US) 2020-12-30 — — WO disclosed
EP-2856528-B1 METAL COMPLEXES COMPRISING CONDENSED HETEROAROMATIC RINGS MERCK PATENT GMBH (DE) 2019-07-03 — — EP disclosed
US-9879177-B2 Metal complexes comprising condensed heteroaromatic rings MERCK PATENT GMBH (DE) 2018-01-30 — — US disclosed
US-7741329-B2 N-aroyl cyclic amines SMITHKLINE BEECHAM LIMITED (GB) 2010-06-22 — — US disclosed
US-20090093478-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.I.C. 2009-04-09 — — US disclosed
US-20090029986-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.L.C. 2009-01-29 — — US disclosed
US-20090012073-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.L.C. 2009-01-08 — — US disclosed
US-7432270-B2 N-aroyl cyclic amines SMITHKLINE BEECHAM P.L.C. (GB) 2008-10-07 — — US disclosed
EP-1956020-A2 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity SMITHKLINE BEECHAM PLC (GB) 2008-08-13 — — EP disclosed
EP-1385845-B1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM PLC (GB) 2008-01-09 — — EP disclosed
US-20040143115-A1 N-aroyl cyclic amines SMITHKLINE BEECHAM LIMITED (GB) 2004-07-22 — — US disclosed
EP-1385845-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM PLC (GB) 2004-02-04 — — EP disclosed
WO-2002090355-A1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM P.L.C. (GB) 2002-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012073-A1 N-AROYL CYCLIC AMINES AANAT, MAOA, MAOB BCHE 249/4885ACHE 121/4885ALDH1A1 467/4885
US-20090093478-A1 N-AROYL CYCLIC AMINES AANAT, MAOA, MAOB BCHE 249/4885ACHE 121/4885ALDH1A1 467/4885
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 BCHE 171/4885ACHE 834/4885ALDH1A1 1920/4885
US-20090029986-A1 N-AROYL CYCLIC AMINES AANAT, MAOA, MAOB BCHE 249/4885ACHE 121/4885ALDH1A1 467/4885
US-20040143115-A1 N-aroyl cyclic amines HCRTR1, HCRTR2, CNR1 BCHE 1702/4885ACHE 2610/4885ALDH1A1 674/4885
US-20230102554-A1 HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF PDGFRB, PDGFRA, FGFR1 BCHE 4679/4885ACHE 4283/4885ALDH1A1 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.